Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDC-501 · 1 trial · 1 indication
M-Protein response evaluated every 4 weeks through urine and serum electrophoresis.
| Name | Type | Description |
|---|---|---|
| CDC-501 | DRUG | - |
* Subject must be diagnosed with multiple myeloma (with measurable M-Protein in serum and/or urine), and be considered to have disease progression after at least two cycles of treatment or have relapsed after treatment. * Subject must understand and voluntarily sign an informed consent document. * S...
Top 20 of 25 competitors
CDC-501 is an investigational small molecule being studied for the treatment of multiple myeloma, a cancer of plasma cells. It is being developed by Bristol-Myers Squibb Company (BMY) and has been evaluated in patients with relapsed or refractory multiple myeloma.
CDC-501 is a small molecule therapeutic being investigated for multiple myeloma. Its specific molecular target has not been disclosed in available clinical trial information, so its mechanism of action is not publicly detailed.
CDC-501 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company has conducted clinical research on this investigational drug for multiple myeloma.
CDC-501 has completed a Phase 2 clinical trial in patients with relapsed or refractory multiple myeloma. The trial, which enrolled 102 participants, was conducted in the United States and has been completed, meaning the drug is no longer in active clinical development according to available records.
CDC-501 has been studied in one clinical trial, identified as NCT00044018, titled "CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma." This Phase 2 trial enrolled 102 patients with multiple myeloma in the United States and has been completed.
CDC-501 is an investigational drug and is not FDA approved. It has been evaluated in a completed Phase 2 clinical trial for relapsed or refractory multiple myeloma, but no approval status has been established based on available information.